12th EDRN Scientific Workshop - Thursday 25 March Agenda

20th Year of EDRN: Making Cancer Detection Possible

Thursday, March 25, 2021 (10:00 a.m. - 7:00 p.m. Eastern Daylight Time)

10:00 a.m. - 10:05 a.m. EDT
(all times Eastern Daylight Time)


  • Joshua LaBaer, MD, PhD, Arizona State University/The Biodesign Institute
  • Arul Chinnaiyan, MD, PhD, University of Michigan
  • Sudhir Srivastava, PhD, MPH, National Cancer Institute
10:05 a.m. - 10:25 a.m. EDT

34: Clinical Perspectives on Biomarker Research

  • Bruce Johnson, MD, Dana-Farber Cancer Institute
10:25 a.m. - 10:30 a.m. EDT


10:30 a.m. - 11:50 p.m. EDT

Session 7 - Regulatory, Reimbursement and Entrepreneurship Biomarker Research


  • Sudhir Srivastava, PhD, MPH, National Cancer Institute
  • Robert Schoen, MD, University of Pittsburgh Cancer Institute
10:30 a.m. - 10:45 p.m. EDT

35: FDA Collaborative on Next Gen Sequencing and its Relevance to Liquid Biopsy for Early Detection

  • James Willey, MD, University of Toledo
10:45 a.m. - 10:50 a.m. EDT


10:50 a.m. - 11:05 a.m. EDT

36: Food and Drug Administration Perspective

  • Wendy Rubinstein, MD, PhD, Director of Personalized Medicine
11:05 a.m. - 11:10 a.m. EDT


11:10 a.m. - 11:25 a.m. EDT

37: From the Lab to Market:  Opportunities from the NCI Small Business Innovation Research (SBIR) Program

  • Michael Weingarten, MA, Director, Small Business Innovation Research, National Cancer Institute
11:25 a.m. - 11:30 a.m. EDT


11:30 a.m. - 11:50 a.m. EDT


11:50 a.m. - 12:50 p.m. EDT

EDRN Poster Highlights Session: Lightning Talks (5 minute Presentations)

NCI Program Directors:

  • Lynn Sorbara, PhD, National Cancer Institute
  • Natalie Abrams, PhD, National Cancer Institute
11:50 p.m. - 11:55 a.m. EDT

38: GPQuant: An Algorithm for Identification and Quantification of Glycopeptides with Different Glycoforms and Its Application to a Large-scale Quantitative Analysis of Urinary Glycopeptides from Aggressive Prostate Cancer

  • Shao-Yung Chen, PhD, Johns Hopkins University School of Medicine
11:55 a.m. - 12:00 p.m. EDT

39: Elevated EVL Methylation Level in Normal Colon Mucosa is a Potential Risk Biomarker for Metachronous Polyps

  • William Grady, MD, Fred Hutchinson Cancer Research Center
12:00 p.m. - 12:05 p.m. EDT

40: Radiomics and Its Application in the Stratification of Pancreatic Cystic Lesion(S)

  • Sukhwinder Kaur, PhD, University of Nebraska Medical Center
12:05 p.m. - 12:10 p.m. EDT

41: Non-Small Cell Lung Cancer and Peripheral Immunity: Mining the Tumor Macroenvironment

  • Andrew Kossenkov, PhD, The Wistar Institute
12:10 p.m. - 12:15 p.m. EDT

42: High Performance in Risk Stratification of Intraductal Papillary Mucinous Neoplasms by EUS-guided Confocal Laser Endomicroscopy

  • Somashekar Krishna, MD, MPH, Ohio State University Medical Center
12:15 p.m. - 12:20 p.m. EDT

43: Identification of Autoantibody Biomarkers against Post-Translationally Modified Proteins for the Early Detection of Breast Cancer

  • Joshua LaBaer, MD, PhD, Arizona State University/The Biodesign Institute
  • Lusheng Song, PhD, Arizona State University
12:20 p.m. - 12:25 p.m. EDT

44: Feasibility of Targeted Proteomics Analysis of Prostate Cancer Progression Biomarkers in FFPE Biopsy Specimens

  • Tao Liu, PhD, Pacific Northwest National Laboratory
12:25 p.m. - 12:30 p.m. EDT

45: AI and Methodology Transfer for Early Detection of Tumors

  • Ashish Mahabal, PhD, California Institute of Technology
12:30 p.m. - 12:35 p.m. EDT

46: Combining Automated Image Measurements, Blood Biomarkers, and Clinical Data for Improved Decisions in Diagnostic Mammography

  • Jeffrey Marks, PhD, Duke University Medical Center
12:35 p.m. - 12:40 p.m. EDT

47: Intermolecular Profiling of Epigenetic Heterogeneity of Rare Biomarkers

  • Chrissy O'Keefe, PhD, Johns Hopkins University
12:40 p.m. - 12:45 p.m. EDT

48: Volume Doubling Time and Radiomic Features Predict Tumor Behavior of Screen-Detected Lung Cancers

  • Jaileene Perez-Morales, PhD, H. Lee Moffitt Cancer Center and Research Institute, Inc.
12:45 p.m. - 12:50 p.m. EDT

49: Use of the Myprostatescore (MPS) Test for Risk Stratification in Men with a Previous Negative Biopsy: Initial Validation of a Straightforward Testing Approach

  • Michael Sessine, BS, University of Michigan Medical School
12:50 p.m. - 1:10 p.m. EDT


1:10 p.m. - 3:10 p.m. EDT

Poster Viewing Session

3:10 p.m. - 5:00 p.m. EDT


5:00 p.m. - 7:00 p.m. EDT

Poster/Interactive Session & Lightning Talks from Japan Investigators (AMED P-CREATE)

5:00 p.m. - 5:50 p.m. EDT

Poster Viewing Session

5:50 p.m. - 7:00 p.m. EDT

Poster Highlights Session

5:50 p.m. - 6:00 p.m. EDT

50: Initial Clinical Trial for Practical Use of Early Diagnosis Marker of Colon Cancer 

  • Jun Adachi, PhD, NIBIOHN Japan
6:00 p.m. - 6:10 p.m. EDT

51: Possibility for Efficient Pancreatic Cancer Screening Using a Blood Test for Apolipoprotein A2-Isoforms

  • Kazufumi Honda, DDS, PhD, Nippon Medical School
6:10 p.m. - 6:20 p.m. EDT

52: Prediction of Cancer Tissue of Origin by Circulating Mirna Profiles

  • Juntaro Matsuzaki, MD, PhD, Keio University Faculty of Pharmacy
6:20 p.m. - 6:30 p.m. EDT

53: Identification of Glioblastoma-selective Secreted Proteins by Secretome Analysis, and their CSF levels in GBM patients

  • Sumio Ohtsuki, PhD, Kumamoto University
6:30 p.m. - 6:40 p.m. EDT

54: Global Proteomic Analysis of Viable Tissue-Derived Exosomes and Identification of Exo-CAT1 as a Potential Early Detection Marker for Colorectal Cancer

  • Koji Ueda, PhD, Japanese Foundation for Cancer Research
6:40 p.m. - 6:50 p.m. EDT

55: Circulating Cancer-Associated Extracellular Vesicles As Early Detection And Recurrence Biomarkers For Pancreatic Ductal Adenocarcinoma

  • Yusuke Yoshioka, PhD, Tokyo Medical University
6:50 p.m. - 7:00 p.m. EDT

56: Three-dimensional analysis of pancreatic fat by fat-water magnetic resonance imaging provides detailed characterization of pancreatic steatosis with improved reproducibility

  • Shingo Kato, MD, PhD, Yokohama City University Hospital
7:00 p.m. EDT

Adjourn Scientific Workshop

Version 5.1.0